{"nctId":"NCT04949841","briefTitle":"Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials","startDateStruct":{"date":"2021-08-23","type":"ACTUAL"},"conditions":["Chronic Hand Eczema"],"count":801,"armGroups":[{"label":"As-needed treatment with delgocitinib","type":"EXPERIMENTAL","interventionNames":["Drug: Delgocitinib"]}],"interventions":[{"name":"Delgocitinib","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must have met eligibility criteria at screening and baseline in the parent trial (DELTA 1 or DELTA 2).\n* Participants must have completed the treatment period in the parent trial (to be assessed at baseline visit in this extension trial).\n* Participants must have complied with the clinical trial protocol in the parent trial to the satisfaction of the investigator.\n* A woman of childbearing potential must use an acceptable method of birth control throughout the trial up until the end-of-treatment/early termination visit.\n\nExclusion Criteria:\n\n* Participants who prematurely discontinued treatment with IMP or initiated rescue medication in the parent trial.\n* Participants who experienced any adverse event (AE) during participation in the parent trial, which precludes further treatment with delgocitinib cream 20 mg/g in the judgement of the investigator.\n* Any medical or psychiatric condition that could put the participant at undue risk by participating in the trial, or which, by the investigator's judgment, makes the participant inappropriate for the trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Treatment-emergent Adverse Events From Baseline up to Week 38","description":"An AE will be considered treatment emergent if it started after the baseline visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1238","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With IGA-CHE Score at Each Scheduled Visit From Baseline up to Week 36","description":"The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"345","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"436","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"413","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"414","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"407","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"401","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"415","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"408","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"395","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"300","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With IGA-CHE Score of 0 (Clear) or 1 (Almost Clear) at Each Scheduled Visit From Baseline up to Week 36.","description":"The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null}]}]}]},{"type":"SECONDARY","title":"HECSI Score at Each Scheduled Visit From Baseline up to Week 36","description":"The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \\[except fingertips\\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":"36.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":"27.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":"25.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":"23.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":"21.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"22.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.7","spread":"19.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":"19.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":"20.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":"20.6"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HECSI-75 at Each Scheduled Visit From Baseline up to Week 36","description":"The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \\[except fingertips\\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-75 is defined as at least 75% improvement in HECSI score from parent trial baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"347","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"391","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"415","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"411","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"432","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"438","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"409","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"414","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"411","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"452","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HECSI-90 at Each Scheduled Visit From Baseline up to Week 36","description":"The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \\[except fingertips\\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from parent trial baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"224","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"236","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"220","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"291","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":801},"commonTop":["COVID-19","Nasopharyngitis","Upper respiratory tract infection","Hand dermatitis","Influenza"]}}}